Search Protocols under revision. Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapyHematologic NeoplasmsProtocol groupIndolent LymphomasTransplantationDiseaseMantle Cell LymphomaStem Cell Transplantation, AutologousSubgroupICD10C83.1Z94.80MeSHLymphoma, Mantle-CellTransplantation, AutologousSequenceTRIANGLEChemotherapyChemo-substanceCytarabineMelphalanChemo-substanceCytarabineMelphalanChemo-substanceCytarabineMelphalanChemo-substanceCytarabineMelphalanNo. Substances2 RadiotherapySupportive therapySupportive substanceAciclovirBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneFosaprepitantGranisetronSupportive substanceAciclovirBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneFosaprepitantGranisetronSupportive substanceAciclovirBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneFosaprepitantGranisetronSupportive substanceAciclovirBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneFosaprepitantGranisetronNo. Substances6Protocol classificationTherapy classificationcurrent standardIntensityHochdosis, myeloablativTherapy indicationseveral possibleTherapy phaseautologous stem cell transplantationTherapy intentioncurativeRisksEmetogenicity (MASCC/ESMO) only studiesPublicationAuthorDreyling MDiseaseMantelzelllymphom, Stadium II-IV, 18-65 J., transplantfähig, Erstlinie, ECOG 0-2OriginLMU University Hospital, Munich, Germany, TRIANGLE StudyProtocols in Revision 1 protocol foundTHAM - Cytarabine 1500 / Melphalan 140 / TBI, prior to Stem Cell Transplantation, Autologous, Mantle Cell Lymphoma (PID3165 V1.0)
